<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03090529</url>
  </required_header>
  <id_info>
    <org_study_id>1725/2014</org_study_id>
    <nct_id>NCT03090529</nct_id>
  </id_info>
  <brief_title>The Role of Exercise Training in the Treatment of Resistant Hypertension</brief_title>
  <acronym>EnRIcH</acronym>
  <official_title>The Role of Exercise Training in the Treatment of Resistant Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aveiro University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Institute of Maia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardiology Department, Hospital Infante D. Pedro, Centro Hospitalar do Baixo Vouga</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hypertension and Cardiovascular Unit, Hospital Pedro Hispano, ULS Matosinhos</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cintesis &amp; Departamento de Medicina da Faculdade de Medicina do Porto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aveiro University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to assess whether exercise training reduces ambulatory
      blood pressure in patients with resistant hypertension. To accomplish these goals 60 patients
      with resistant hypertension will be recruited and randomized into exercise training or
      control groups and followed up for 6 months. The patients in the exercise group will
      participate in a 3-month outpatient program. The control group will receive usual medical
      care. At baseline, after the intervention and 3 months after the end of the intervention both
      groups will undergo several evaluations, including casual and ambulatory blood pressure, body
      composition, cardiorespiratory fitness, quality of life, arterial stiffness, autonomic
      function, and endothelial and inflammatory biomarkers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ambulatory blood pressure</measure>
    <time_frame>Change from Baseline in Blood Pressure at 3 months</time_frame>
    <description>Blood pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Casual blood pressure</measure>
    <time_frame>Change from baseline to 3 months</time_frame>
    <description>Blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>Change from baseline to 3 months</time_frame>
    <description>Body composition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Change from baseline to 3 months</time_frame>
    <description>Health-related quality of life will be evaluated by the Short-Form 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial stiffness</measure>
    <time_frame>Change from baseline to 3 months</time_frame>
    <description>Carotid-femoral pulse wave velocity, central pressures and aortic augmentation index and augmentation pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability</measure>
    <time_frame>Change from baseline to 3 months</time_frame>
    <description>Recordings of R-R interval data; The R-R interval will be analyzed using time domain, frequency domain and Poincare´ plot techniques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating number of endothelial progenitor cells, circulating endothelial cells, nitric oxide and endothelial Nitric Oxide Synthase</measure>
    <time_frame>Change from baseline to 3 months</time_frame>
    <description>These markers will inform endothelial function, damage and repair</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>Change from baseline to 3 months</time_frame>
    <description>Plasma levels of inflammatory and anti-inflammatory biomarkers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress</measure>
    <time_frame>Change from baseline to 3 months</time_frame>
    <description>Plasma levels of oxidative stress and antioxidant markers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily physical activity</measure>
    <time_frame>Change from baseline to 3 months</time_frame>
    <description>Physical activity will be measured during 7 consecutive days using an accelerometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary intake</measure>
    <time_frame>Change from baseline to 3 months</time_frame>
    <description>Dietary intake will be assessed using a 4-day food diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VO2 max</measure>
    <time_frame>Change from baseline to 3 months</time_frame>
    <description>VO2 max will be determined by the Chester step test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Resistant Hypertension</condition>
  <arm_group>
    <arm_group_label>Exercise group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The 12-week exercise-training program will include three sessions of aerobic exercise per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group will receive usual medical care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise Group</intervention_name>
    <description>The 12-week exercise-training program will include three sessions of aerobic exercise per week</description>
    <arm_group_label>Exercise group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: confirmed resistant hypertension, who in the previous 3 months had
        unchanged medication

        Exclusion Criteria:

          1. Patients with secondary hypertension

          2. Evidence of target organ damage

          3. Patients with heart failure

          4. Previous cardiovascular event

          5. Peripheral artery disease

          6. Renal failure

          7. Chronic obstructive pulmonary disease

          8. Systolic office blood pressure superior to 180 mmHg

          9. Biomechanical limitations to physical activity

         10. Those participating in regular physical activity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Mesquita Bastos, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Infante D. Pedro, Centro Hospitalar do Baixo Vouga</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fernando Ribeiro, PhD</last_name>
    <phone>+351234372455</phone>
    <phone_ext>27113</phone_ext>
    <email>fernando.ribeiro@ua.pt</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alberto Alves, PhD</last_name>
    <phone>+351229866000</phone>
    <phone_ext>1313</phone_ext>
    <email>ajalves@ismai.pt</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiology Department, Hospital Infante D. Pedro, Centro Hospitalar do Baixo Vouga</name>
      <address>
        <city>Aveiro</city>
        <zip>3800</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Mesquita-Bastos, MD, PhD</last_name>
      <email>mesquitabastos@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hypertension and Cardiovascular Unit, Hospital Pedro Hispano, ULS Matosinhos</name>
      <address>
        <city>Matosinhos</city>
        <zip>4464-513</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Polonia, MD, PhD</last_name>
      <email>jjpolonia@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jorge Polonia, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>March 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2017</study_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aveiro University</investigator_affiliation>
    <investigator_full_name>Fernando Ribeiro</investigator_full_name>
    <investigator_title>Adjunct Professor</investigator_title>
  </responsible_party>
  <keyword>Exercise training</keyword>
  <keyword>Ambulatory blood pressure</keyword>
  <keyword>Resistant Hypertension</keyword>
  <keyword>Nitric Oxide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

